Analyst firms · UBS · TEVA
UBS TEVA price target and rating history
Teva Pharmaceutical Industries Limited (TEVA) · Health Care
UBS rates Teva Pharmaceutical Industries Limited (TEVA) Buy with a $13 price target, as of its latest action on Nov 27, 2023. It has published 4 rating actions on TEVA since June 2022, including 2 upgrades and 1 downgrade. Across 6 firms with a TEVA price target in the last 12 months, the median target is $47.50.
- Current rating
- Buy
- Price target
- $13
- Median target, all firms
- $47.50
- Actions on TEVA
- 4
UBS price target on TEVA
Every UBS rating on TEVA
- Nov 27, 2023
- Jul 6, 2023
- Nov 4, 2022DowngradeUBS downgrades to Sell from Neutral
- Jun 14, 2022
How other firms rate TEVA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $52 | Nov 2, 2026 |
| TD Cowen | Buy | $55 | Oct 1, 2026 |
| Oppenheimer | Outperform | $50 | Sep 23, 2026 |
| Leerink Partners | Outperform | $45 | Sep 9, 2026 |
| Barclays | Overweight | $35 | Dec 9, 2025 |
| Scotiabank | Sector Outperform | $35 | Dec 5, 2025 |
Questions about UBS and TEVA
- What is UBS's price target for TEVA?
- UBS's latest stated price target for Teva Pharmaceutical Industries Limited (TEVA) is $13, from its action on Nov 27, 2023.
- What is UBS's rating on TEVA?
- UBS rates TEVA Buy, a bullish rating, as of Nov 27, 2023.
- When did UBS last change its view on TEVA?
- On Nov 27, 2023, UBS upgrades to Buy from Neutral, price target $11 to $13.
- How does UBS's TEVA target compare with other analysts?
- Across 6 firms with a TEVA price target in the last 12 months, the median target is $47.50.
More TEVA rating histories
All UBS ratingsTEVA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.